H Refsum1, A D Smith. 1. Department of Pharmacology, University of Oxford, Oxford, UK.
Abstract
OBJECTIVE: To examine the possible association of holotranscobalamin, the active fraction of serum cobalamin, with Alzheimer's disease. METHODS: 51 patients with pathologically confirmed Alzheimer's disease and 65 cognitively screened elderly controls were studied. Serum holotranscobalamin was measured by a new solid phase radioimmunoassay. RESULTS: Geometric mean levels showed no significant case-control differences for serum total cobalamin, but lower levels of holotranscobalamin in Alzheimer's disease (41.1 pmol/l) than in controls (57.1 pmol/l) (p < 0.001). The odds ratio of Alzheimer's disease was significant for low holotranscobalamin but not for low total cobalamin. CONCLUSIONS: Disturbed cobalamin status is common in Alzheimer's disease and accordingly measurement of holotranscobalamin should be considered in the assessment of cognitively impaired patients.
OBJECTIVE: To examine the possible association of holotranscobalamin, the active fraction of serum cobalamin, with Alzheimer's disease. METHODS: 51 patients with pathologically confirmed Alzheimer's disease and 65 cognitively screened elderly controls were studied. Serum holotranscobalamin was measured by a new solid phase radioimmunoassay. RESULTS: Geometric mean levels showed no significant case-control differences for serum total cobalamin, but lower levels of holotranscobalamin in Alzheimer's disease (41.1 pmol/l) than in controls (57.1 pmol/l) (p < 0.001). The odds ratio of Alzheimer's disease was significant for low holotranscobalamin but not for low total cobalamin. CONCLUSIONS: Disturbed cobalamin status is common in Alzheimer's disease and accordingly measurement of holotranscobalamin should be considered in the assessment of cognitively impairedpatients.
Authors: Simon M Collin; Chris Metcalfe; Helga Refsum; Sarah J Lewis; Luisa Zuccolo; George Davey Smith; Lina Chen; Ross Harris; Michael Davis; Gemma Marsden; Carole Johnston; J Athene Lane; Marta Ebbing; Kaare Harald Bønaa; Ottar Nygård; Per Magne Ueland; Maria V Grau; John A Baron; Jenny L Donovan; David E Neal; Freddie C Hamdy; A David Smith; Richard M Martin Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-05-25 Impact factor: 4.254
Authors: Lindsay H Allen; Joshua W Miller; Lisette de Groot; Irwin H Rosenberg; A David Smith; Helga Refsum; Daniel J Raiten Journal: J Nutr Date: 2018-12-01 Impact factor: 4.798
Authors: Amy L Anderson; Tamara B Harris; Frances A Tylavsky; Sara E Perry; Denise K Houston; Trisha F Hue; Elsa S Strotmeyer; Nadine R Sahyoun Journal: J Am Diet Assoc Date: 2011-01
Authors: Edward Suarez-Moreira; Luciana Hannibal; Clyde A Smith; Roberto A Chavez; Donald W Jacobsen; Nicola E Brasch Journal: Dalton Trans Date: 2006-09-21 Impact factor: 4.390
Authors: Sylvia M Dobbs; R John Dobbs; Clive Weller; André Charlett; Aisha Augustin; David Taylor; Mohammad A A Ibrahim; Ingvar Bjarnason Journal: J Neurovirol Date: 2015-06-20 Impact factor: 2.643